Back to Journals » Vascular Health and Risk Management » Volume 8

Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic

Authors Volpe M, Tocci G

Received 18 November 2011

Accepted for publication 23 December 2011

Published 11 June 2012 Volume 2012:8 Pages 371—380

DOI https://doi.org/10.2147/VHRM.S28359

Review by Single-blind

Peer reviewer comments 2

Massimo Volpe,1,2 Giuliano Tocci2

1Division of Cardiology, Department of Clinical and Molecular Medicine, University of Rome, Sapienza, Sant'Andrea Hospital, Rome, 2IRCCS Neuromed, Pozzilli, Italy

Abstract: Hypertension is a growing global health problem, and is predicted to affect 1.56 billion people by 2025. Treatment remains suboptimal, with control of blood pressure achieved in only 20%–35% of patients, and the majority requiring two or more antihypertensive drugs to achieve recommended blood pressure goals. To improve blood pressure control, the European hypertension guidelines recommend that angiotensin II receptor blockers (ARBs) or angiotensin-converting enzyme inhibitors (ACEIs) are combined with calcium channel blockers (CCBs) and/or thiazide diuretics. The rationale for this strategy is based, in part, on their different effects on the renin-angiotensin system, which improves antihypertensive efficacy. Data from a large number of trials support the efficacy of ACEIs or ARBs in combination with CCBs and/or hydrochlorothiazide (HCTZ). Combining two different classes of antihypertensive drugs has an additive effect on lowering of blood pressure, and does not increase adverse events, with the ARBs showing a tolerability advantage over the ACEIs. Among the different ARBs, olmesartan medoxomil is available as a dual fixed-dose combination with either amlodipine or HCTZ, and the increased blood pressure-lowering efficacy of these two combinations is proven. Triple therapy is required in 15%–20% of treated uncontrolled hypertensive patients, with a renin-angiotensin system blocker, CCB, and thiazide diuretic considered to be a rational combination according to the European guidelines. Olmesartan, amlodipine, and HCTZ are available as a triple fixed-dose combination, and significant blood pressure reductions have been observed with this regimen compared with the possible dual combinations. The availability of these fixed-dose combinations should lead to improvement in blood pressure control and aid compliance with long-term therapy, optimizing the management of this chronic condition.

Keywords: angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, triple therapy, hypertension

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other article by this author:

Readers of this article also read:

Physical activity in patients with type 2 diabetes and hypertension – insights into motivations and barriers from the MOBILE study

Duclos M, Dejager S, Postel-Vinay N, di Nicola S, Quéré S, Fiquet B

Vascular Health and Risk Management 2015, 11:361-371

Published Date: 29 June 2015

Prevention of stent thrombosis: challenges and solutions

Reejhsinghani R, Lotfi AS

Vascular Health and Risk Management 2015, 11:93-106

Published Date: 27 January 2015

Safety and effectiveness of a fixed-dose combination of olmesartan, amlodipine, and hydrochlorothiazide in clinical practice

Bramlage P, Fronk EM, Wolf WP, Smolnik R, Sutton G, Schmieder RE

Vascular Health and Risk Management 2015, 11:1-8

Published Date: 17 December 2014

Patterns of warfarin use and subsequent outcomes in atrial fibrillation in primary care practices

Ewen E, Zhang Z, Simon TA, Kolm P, Liu X, Weintraub WS

Vascular Health and Risk Management 2012, 8:587-598

Published Date: 19 October 2012

The prevention and regression of atherosclerotic plaques: emerging treatments

Kalanuria AA, Nyquist P, Ling G

Vascular Health and Risk Management 2012, 8:549-561

Published Date: 25 September 2012

Challenges for heart disease stem cell therapy

Hoover-Plow J, Gong Y

Vascular Health and Risk Management 2012, 8:99-113

Published Date: 17 February 2012